Pramipexole Dihydrochloride
NDC Package 69844-044-01
Package Information
Pramipexole Dihydrochloride is pramipexole is used alone or with other medications to treat Parkinson's disease. Marketed by Graviti Pharmaceuticals Private Limited, this product is identified by NDC 69844-044 and is authorized under FDA application ANDA211088.
Identification & Billing
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 69844 - Graviti Pharmaceuticals Private Limited
- 69844-044 - Pramipexole Dihydrochloride
- 69844-044-01 - 90 TABLET in 1 BOTTLE
- 69844-044 - Pramipexole Dihydrochloride
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 69844-044-01 identifies a specific commercial package of 90 tablet in 1 bottle of Pramipexole Dihydrochloride, labeled by Graviti Pharmaceuticals Private Limited. This is formulated for use and contains as the active substance.
Is this product currently listed with the FDA?
This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Graviti Pharmaceuticals Private Limited on April 06, 2020. The current certification is valid through September 23, 2022.
What are the primary indications for this medication?
Pramipexole is used alone or with other medications to treat Parkinson's disease. It can improve your ability to move and decrease shakiness (tremor), stiffness, slowed movement, and unsteadiness. It may also decrease the number of episodes of not being able to move ("on-off syndrome"). This medication is also used to treat a certain medical condition (restless legs syndrome - RLS) that causes an unusual urge to move the legs. Symptoms usually occur at night along with uncomfortable/unpleasant feelings in the legs. This medication can decrease these symptoms and thereby improve sleep. Pramipexole is a dopamine agonist that works by helping to restore the balance of a certain natural substance (dopamine) in the brain.
How is this Graviti Pharmaceuticals Private Limited product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 69844004401. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.